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ABSTRACT
A Brazilian Health Technology Assessment Bulletin (BRATS) article 
regarding scientific evidence of the efficacy and safety of methylphenidate 
for treating attention deficit hyperactivity disorder (ADHD) has caused 
much controversy about its methods. Considering the relevance of BRATS 
for public health in Brazil, we critically reviewed this article by remaking 
the BRATS search and discussing its methods and results. Two questions 
were answered: did BRATS include all references available in the literature? 
Do the conclusions reflect the reviewed articles? The results indicate that 
BRATS did not include all the references from the literature on this subject 
and also that the proposed conclusions are different from the results of the 
articles chosen by the BRATS authors themselves. The articles selected by 
the BRATS authors showed that using methylphenidate is safe and effective. 
However, the BRATS final conclusion does not reflect the aforementioned 
and should not be used to support decisions on the use of methylphenidate.
DESCRIPTORS: Child. Attention Deficit Disorder with Hyperactivity, 
Drug Therapy. Methylphenidate, therapeutic use. Evaluation of the 
Efficacy-Effectiveness of Interventions. 
Comments DOI:10.1590/S0034-8910.2015049005966
Felipe Salles Neves MachadoI
Sheila Cavalcante CaetanoI
Ana Gabriela HounieI
Sandra ScivolettoII
Mauro MuszkatIII
Ivete Gianfaldoni GattásI
Erasmo Barbante CasellaIV
Ênio Roberto de AndradeII
Guilherme Vanoni PolanczykII
Maria Conceição do RosárioI
2 Methylphenidate use in children with ADHD Machado FSN et al
The March 2014 issue of the Boletim Brasileiro de 
Avaliação de Tecnologias em Saúde (BRATS – Brazilian 
Health Technology Assessment Bulletin), published 
by the Brazilian Secretariat of Science, Technology, 
and Strategic Inputs, aimed at evaluating scientific 
evidence of the efficacy and safety of the treatment 
with methylphenidate in children and adolescents with 
attention deficit hyperactivity disorder (ADHD).a The 
BRATS authors concluded that the studies were gener-
ally of low methodological quality, with few follow-
up weeks and low generalization. They do not recom-
mend using methylphenidate, despite the literature 
indicating otherwise.
Health technology assessments are extremely impor-
tant, especially those applied in the Brazilian Unified 
Health System (SUS). Rational use of medicines 
should always be encouraged and any therapeutic 
strategy should only be used after a thorough clin-
ical evaluation of the child, the family and his/her 
behavior at school and in the community. As a conse-
quence of their dissemination and prestige, health 
technology assessments have the potential to be 
the main parameter for decision-making by public 
managers in Brazil. Therefore, documents such as this 
must be based on high-quality scientific information 
RESUMO 
O Boletim Brasileiro de Avaliação de Tecnologias em Saúde (BRATS), em 
matéria sobre as evidências científicas da eficácia e segurança do metilfenidato 
para o transtorno de déficit de atenção e hiperatividade (TDAH), gerou 
controvérsias sobre sua metodologia. Considerando a relevância do BRATS para 
a saúde pública no Brasil, realizou-se análise crítica dessa matéria ao refazer 
a busca do BRATS e discutir sua metodologia e achados. Foram respondidas 
duas perguntas: o BRATS incluiu todas as referências disponíveis na literatura? 
As conclusões refletiram os textos revisados? Identificou-se que o BRATS 
não incluiu todas as referências da literatura sobre o tema e que as conclusões 
propostas estão diferentes dos resultados dos artigos escolhidos pelos próprios 
autores do BRATS. Os artigos selecionados pelos autores do BRATS apontam 
para a eficácia e segurança do uso do metilfenidato. Entretanto, a conclusão 
final dos autores não reflete isso e não deveria ser usada como referência para 
orientar decisões sobre o uso do metilfenidato.
DESCRITORES: Criança. Transtorno do Déficit de Atenção com 
Hiperatividade, Quimioterapia. Metilfenidato, uso terapêutico. 
Avaliação de Eficácia-Efetividade de Intervenções. 
INTRODUCTION
and their conclusions should not lead health profes-
sionals to doubts.16,b
The following two questions were established in order 
to critically review BRATS: 1) Did the report include 
all references available in the literature on the subject? 
2) Did the conclusions proposed by the report clearly 
and objectively describe the results of the texts reviewed 
by the authors? In order to address these questions, we 
gathered researchers, professors and experts with exten-
sive ADHD research knowledge.
SEARCH METHOD ANALYSIS
BRATS edition
The authors of the cited edition of BRATS performed 
searches in the following databases: Medline (PubMed), 
the Cochrane Library, the Centre for Reviews and 
Dissemination (CRD), the National Institute for Health 
and Care Excellence (NICE) and the Canadian Agency 
for Drugs and Technologies in Health (CADTH). 
However, some databases that we consider relevant 
were not included, such as: the American Psychological 
Association (PsycINFO); Literatura Latino-Americana 
em Ciências da Saúde (LILACS – Latin American 
a Rede Brasileira de Avaliação de Tecnologias em Saúde. Metilfenidato no tratamento de crianças com transtorno de déficit de atenção e 
hiperatividade. BRATS Bol Bras Aval Info Health [Internet]. 2014 [cited 2015 jan 31];8(23):1-12. Available from: http://200.214.130.94/rebrats/
publicacoes/brats23.pdf
b Ministério da Saúde. Diretrizes metodológicas: elaboração de pareceres técnico-científicos [Internet]. 3.ed. rev. atual. Brasília (DF); 2011 
[cited 2015 jan 31]. (Série A. Normas e Manuais Técnicos). Available from: http://200.214.130.94/rebrats/publicacoes/DiretrizesPTC.pdf 
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Literature in Health Sciences); Elsevier (Embase); 
and the Science Citation Index from the Institute for 
Scientific Information (ISI) from the United States, as 
well as their Web of Science and SciSEARCH search 
interfaces. The following key words were used for the 
aforementioned searches: “Methylphenidate”, “chil-
dren” and “attention-deficit disorder”. However, this 
search strategy was quite restrictive because it made no 
use of electronic search mechanisms that are important 
for including all relevant articles from a large number of 
related terms, such as the “MeSH terms” mechanism in 
PubMed. In addition, the term “hyperkinetic disorders”, 
which was adopted by the International Classification of 
Diseases (ICD)17 and accepted and recommended by the 
Brazilian Ministry of Health for providing any mental 
health care in Brazil, was not included.17
NEW SEARCH METHOD
We conducted another search, in accordance with 
the recommendations for systematic reviews. In this 
search, the terms “Methylphenidate”, “children”, 
“attention-deficit disorder” or “hyperkinetic disorders” 
were used. We found 563 studies in the Medline data-
base with the same filters used by BRATS (Systematic 
Reviews; Randomized Controlled Trial; and Publication 
date from 1/1/2000 to 12/31/2013). We used the exclu-
sion criteria proposed by BRATS and found 54 articles 
that were not included in the BRATS search.
The BRATS authors did not explain why, despite the 
significant number of studies with rigorous method-
ology on psychostimulants, they chose to include only 
seven studies, four of which were systematic reviews 
with meta-analysis, one was a randomized clinical trial 
and two were health technology assessments. It was 
clear that choosing these criteria dramatically reduced 
the number of assessed studies. From a methodolog-
ical point of view, that fact alone makes any systematic 
review incomplete.
In regard to the results presented, only five of the seven 
articles were described in a table that presented different 
data (e.g., standardized mean difference, response rates, 
and medical difference) in a single column without 
clarifying the reasons for such decision. The studies 
considered were published from the year 2000 onwards, 
about children treated with methylphenidate compared 
with those given medicinal alternatives or placebos. 
Selection was directed by the inattention, hyperac-
tivity, impulsiveness, adverse events, productivity and 
behavioral outcomes.
It is worth emphasizing that all articles had the 
following statements regarding methylphenidate use in 
children and adolescents: “presents significant superi-
ority for reducing symptoms of hyperactivity compared 
with placebos”;12,14 “greater effectiveness than other 
medications”;4,10 “short- and long-term release have 
similar effects”.13 According to Schachter et al14 
(2001), methylphenidate has an effect size of between 
0.54 and 0.78, which is regarded as good, and proves 
the efficacy of methylphenidate for treating ADHD 
when compared with placebos.14 Prasad et al12 (2013) 
demonstrated the benefit of methylphenidate when 
compared to placebos, as well as the benefits of high 
doses when compared with low doses for the execu-
tion of tasks, productivity in the classroom and accu-
racy in school activities. Hanwella et al4 (2011) found 
that methylphenidate has efficacy and acceptability 
similar to atomoxetine, however the long-acting meth-
ylphenidate is more effective and should be considered 
as first-line therapy for children and adolescents with 
ADHD. Two other studies also concluded that treat-
ment with methylphenidate was more effective than 
using buspirone10 or placebos.11
COMMENTS
Despite the aforementioned, it is worth noting that 
the conclusions from BRATS are different from those 
presented in the original articles.4,10,12-14 More specifically, 
there are disagreements regarding the following points:
1. “(...) Evidence regarding the efficacy and safety of 
treatment with methylphenidate in children and tee-
nagers, in general, is of low methodological quality, 
with a short follow-up period and little generaliza-
tion capacity (...)”.a
This statement is contradictory because the authors 
themselves performed a study with many method-
ological biases, besides not specifying the criteria 
for including the five reviewed studies and for quali-
fying them as the only ones to present good method-
ological quality.
There are currently many articles of high methodolog-
ical quality in the literature that were not included in 
BRATS, such as the Multimodal Treatment of Attention 
Deficit Hyperactivity Disorder Study (MTA).9,11 The 
MTA is one of the multicenter studies of high meth-
odological quality on ADHD, funded by the National 
Institute of Mental Health and designed to evaluate the 
main treatments for ADHD, including behavior therapy, 
medication, and a combination of the two. Its results 
have been published in articles since 1999 and have 
shown that methylphenidate is effective and safe,5,9 in 
addition to significantly improving the child’s symp-
toms and quality of life, as well as that of the child’s 
family, peers and teachers.1
Methylphenidate is one of the most widely studied and 
used medications for treating ADHD. Its safety and 
effectiveness were duly confirmed by methodologically 
rigorous studies in children and adolescents.2,3,10,12-15
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2. “(...) heterogeneity among the studies was one of 
the most frequent problems in the selected syste-
matic reviews (...)”.a
The effectiveness outcomes, which were assessed by 
varied diagnostic criteria and instruments, presented 
heterogeneous results that, in general, did not show 
superior clinical benefit compared with pharmacolog-
ical alternatives or with different doses and forms of 
methylphenidate (...)”.a
Based on the fact that the criteria used for selection 
were defined by the authors themselves, it is difficult 
to understand why articles with similar designs were 
not filtered. However, regardless of the assessment 
tools and outcome variables, the five studies chosen 
by the BRATS revealed moderate effect sizes when 
methylphenidate was compared to placebos.12,14 The 
fact that there are studies with different methodologies 
but similar results, in terms of effectiveness, reassures 
the effectiveness of methylphenidate.
The fact that different formulations have similar results 
is positive, as it indicates that using methylphenidate, 
in all its forms, is beneficial for patients.13
3. “(...) With regard to the drug’s safety profile, studies 
have shown that some of the most common adverse 
effects were: appetite suppression, increased alert-
ness and euphoria, insomnia, headaches, stomach 
pain and dizziness (...)”.a
The literature describes such adverse effects at three 
grade levels: mild, moderate and severe. Despite the 
above sentence being correct, all five articles reported 
that the side effects of using methylphenidate were 
considered mild.2,3,7,9 The BRATS authors did not 
mention the frequency or intensity with which each 
adverse event occurs or anything about the importance 
of the side effects. Therefore, they did give the impres-
sion that these are common.
However, many studies in the literature showed that the 
possible side effects of methylphenidate are considered 
mild, are well tolerated and do not outweigh the treat-
ment benefits.2,3 Methylphenidate, in its various forms, 
showed that not only it helps children with ADHD by 
reducing extreme and improper hyperactivity, but also 
it significantly improves attention and concentration 
as well as function execution in their various dimen-
sions. Proper treatment makes it possible for the child 
to develop as fully as possible at school and in other 
environments, as well as in the cognitive, affective and 
social dimensions.
4. “(...) Currently, the drug is increasingly being con-
sumed in Brazil, which is not yet sold on the domes-
tic market as similar or generic. There is evidence 
in existence that states that children who do not 
have ADHD were being medicated and that cases 
of the disease were being needlessly treated (...)”.a
None of the studies included in the review were done 
in Brazil, so it was not clear how this evidence was 
shown. There has been an increasing rate of methyl-
phenidate consumption in Brazil,c due to the fact that 
the measurement starting point was zero. However, 
consumption of the drug is not greater than the disease’s 
prevalence, and national estimates indicate that ADHD 
is still undertreated.8 This point is of extreme relevance 
for future studies. In order to investigate the real reasons 
for the increase in the consumption of psychostimu-
lants in Brazil, it is suggested that answers be given to 
relevant, among others, questions, such as: 1) Is there 
any abuse of methylphenidate? If yes, in which popu-
lation does it occur?; 2) Are there people with ADHD 
who do not have access to medication? 3) Has there 
been an increase in the number of recognized ADHD 
cases? 4) Is there any misuse of psychostimulants by 
professionals who have not been properly trained in 
child and adolescent psychopathology?
5. “(...) Diagnosing this disorder is dimensional, as it 
involves typical patterns of behavior of the age group 
and those presented by the individuals. Moreover, 
symptoms of the disorder can be found in the beha-
vior of individuals with normal development (...)”.a
Despite this statement being correct, it gives rise to ques-
tions regarding the validity of the disorder that is not 
applicable to a document which supposedly uses the prin-
ciples of evidence-based medicine. It would be essential 
to mention the several studies that show the family aggre-
gation of the disorder, its environmental and genetic risk 
factors, the changes in cerebral structure and function 
found in diagnosed individuals and the functional losses 
that occur throughout the disorder’s development. All 
these studies reinforce the validity of ADHD diagnosis.
6. “(...) considering its high potential for abuse and 
dependence, it becomes urgent to have debates that 
address the current problem of improper methylphe-
nidate consumption, alerting the population to its 
misuse, adverse effects and legal consequences (...)”.a
None of the cited articles discuss the potential for meth-
ylphenidate abuse and dependence. Therefore, it is not 
clear how the authors arrived at this conclusion. It is 
important to stress that several studies have shown that 
methylphenidate does not cause chemical dependence,6 
which are results that invalidate the authors’ conclusions.
c Agência Nacional de Vigilância Sanitária (ANVISA). Prescrição e consumo de metilfenidato no Brasil: identificando riscos para o 
monitoramento e controle sanitário. Bol Farmacoepidemiol SNGPC [Internet]. 2012 [cited 2015 jan 31];2(2):1-14. Available from: http://www.
anvisa.gov.br/sngpc/boletins/2012/boletim_sngpc_2_2012_corrigido_2.pdf 
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CONCLUSIONS
Based on the critical analysis of the BRATS, it was 
possible to respond to the questions included, namely: 
the BRATS did not include all references that are 
already available in the literature on the subject; the 
conclusions proposed by the authors were not based 
on the results of the five articles chosen by the authors.
The conclusions arrived at by the BRATS need to be 
reviewed because they do not restrict themselves to 
researched facts and therefore do not obey the meth-
odological rigor that is necessary in scientific studies, 
based on systematic reviews of the literature and 
evidence-based medicine studies. Therefore, such 
conclusions should not offer scientific support to strat-
egies and public policies on the subject.
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